LaslettLJ,Alagona JrP,ClarkIII BA,Drozda JrJP,SaldivarF,WilsonSR,PoeC,HartM., .The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology,2012 Dec 60 S1 -49
AssmannG,Schulte H. The Prospective Cardiovascular, .Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease,1988 Dec 1 1713 -24
IstvanES,DeisenhoferJ, .Structural mechanism for statin inhibition of HMG-CoA reductase,Science. 2001 May 292 1160 -4
Athyros , V., 2004.The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study,Journal of clinical pathology 57 728 -734
Kim, 2008.Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process,International Journal of Pharmaceutics 359 211 -219
Shah , D., 2006.RP-HPLC determination of atorvastatin calcium and amlodipine besylate combination in tablets,Indian journal of pharmaceutical sciences 68 796 -
Kim,M.-S., 2008.Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process,European journal of pharmaceutics and biopharmaceutics 69 454 -465
Anwar , M., 2011.Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats,European Journal of Pharmaceutical Sciences 44 241 -249
Mukharya , A., 2011.Stable and Bio-equivalent Formulation of HMG-CoA reductase inhibitor: Atorvastatin Calcium,International Journal of Pharmaceutical Sciences Letters 2 12 -20
Sievens-Figueroa , L., 2012.Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications,International journal of pharmaceutics 423 496 -508
Aiyalu , R. and K.,Mani, 2012.HPTLC method development, validation, and stress degradation studies for atorvastatin and ezetimibe in multicomponent tablet dosage form,Medicinal Chemistry Research 21 1297 -1301
Attimarad , M., 2017.Capillary Electrophoresis Method Development for Simultaneous Determination of Atorvastatin and Ezetimibe from Solid Dosage Form,Journal of Young Pharmacists 9 120 -
Ertürk , S., 2003.An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets,Journal of pharmaceutical and biomedical analysis 33 1017 -1023
AshutoshKumar,S.,M.Debnath,J. SeshagiriRao, 2014.New Validated RP-HPLC Analytical Method for Simultaneous Estimation of Atorvastatin and Ezetimibe in Bulk Samples as Well in Tablet Dosage Forms by Using PDA Detector,Current drug discovery technologies 11 259 -270
Naveed , S.,SimpleUV, 2014.spectrophotometric assay of Atorvastatin API formulation and their comparative study,Global Journal of Medical Research -
RazaviB,AbdelmelekSB,SongW,O'SheaKE,CooperWJ, .Photochemical fate of atorvastatin (lipitor) in simulated natural waters,2011 Jan 1 625 -31